Aspen in talks with Johnson & Johnson to produce and market COVID-19 vaccine
The company is also looking to expand its COVID-19 vaccine manufacturing under a contract with J&J, from 300 million doses to about 450 million doses by February 2022
South Africa’s Aspen Pharmacare is in talks with Johnson & Johnson over a licence to manufacture, market and sell COVID-19 vaccines in South Africa, according to a company presentation uploaded on its website today.
“If successful with a licence, Aspen will not only have manufacturing, but will also have the rights to its own branded product,” the presentation said.
It said the company is also looking to expand its COVID-19 vaccine manufacturing under a contract with J&J, from 300 million doses to about 450 million doses by February 2022.
- Advertisement -